A Double Blind, Placebo Controlled Trial to Evaluate Role of Probiotic- Bacillus subtilis HU58 syrup on Antibiotic associated Diarrhoea in Children

Synergia Lifesciences Pvt Ltd0 个研究点目标入组 69 人开始时间: 待定最近更新: 2023年4月3日

试验速览

暂无简介。

•1.Children aged 1 to 12 years.
•2.Children undergoing treatment with antibiotics irrespective of indication and type of antibiotics.
•3.AAD defined as passage of three or more liquid or watery stools occurring in a 24-hour period.
•4.Children and Parents willingness to participate in the clinical study and willing to give informed consent/assent.

•1.History of pre-existing diarrhea within the previous 4 weeks.
•2.Subjects requiring hospitalization.
•3.Subjects with severe dehydration requiring intravenous rehydration.
•4.Subjects with bloody and/or purulent stools
•5.Subjects with symptoms or suspicion of an organic lesion of the digestive tract, or with undiagnosed abdominal pain or rectal bleeding or other GI disorder especially ulcerative colitis, Crohnâ??s disease, history of carcinomas of the bowel, malabsorption syndrome, intolerance to certain food types (lactose), functional diarrhea and functional constipation.
•6.Subjects with gastrointestinal surgery.
•7.History of severe chronic systemic diseases, critical/life-threatening illness, or immunodeficiency diseases.
•8.Known hypersensitivity to any of the ingredients in the probiotic product or the placebo.
•9.Use of proton-pump inhibitors, laxatives, or anti-diarrhoeal drugs, as well as use of a probiotic 14 days before and during the study
•10.Participation in another clinical study within 30 days before the beginning or anytime during the duration of the current clinical study.
•11.Any other condition which, in the opinion of the Investigator, prevents the child from participating in the study.

发起方

Synergia Lifesciences Pvt Ltd